AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 13.65 |
Market Cap | 1.78B |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -0.61 |
PE Ratio (ttm) | -22.73 |
Forward PE | n/a |
Analyst | Buy |
Ask | 13.95 |
Volume | 2,355,067 |
Avg. Volume (20D) | 782,360 |
Open | 12.72 |
Previous Close | 12.63 |
Day's Range | 12.26 - 13.88 |
52-Week Range | 12.13 - 19.11 |
Beta | undefined |
About NEO
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fl...
Analyst Forecast
According to 10 analyst ratings, the average rating for NEO stock is "Buy." The 12-month stock price forecast is $19.5, which is an increase of 40.64% from the latest price.
Next Earnings Release
Analysts project revenue of $173.23M, reflecting a 11.36% YoY growth and earnings per share of 0.03, making a 0.00% YoY.